Work

Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences

Year: 2023

Type: article

Source: The Lancet Rheumatology

DOI: 10.1016/s2665-9913(23)00033-4

Authors: Elizabeth R Volkmann, Jeffrey A Sparks, Anna-Maria Hoffmann-Vold, Tracy J Doyle, Paul Emery, Philippe Dieudé

Institutions: University of California, Los Angeles, Brigham and Women's Hospital, Harvard University, Oslo University Hospital, University of Zurich, University Hospital Zurich, University of Leeds, Leeds Teaching Hospitals NHS Trust, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Physiopathologie et Epidémiologie des Maladies Respiratoires

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Gilead Sciences, Harvard University, National Institutes of Health, Genentech, Samsung, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: G1653066117, G556636930, G9000184180, G9000286667, Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases, Joint Biology Consortium Resource-based Center, Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes, Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung Disease, VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics

OpenAlex ID: W4319301296

FWCI: 1.287

Cites: 11

Cited by: 7

Related to: 10